{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:51:08Z","timestamp":1773780668502,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50-CA243786"],"award-info":[{"award-number":["R50-CA243786"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012482","name":"University of Michigan Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["2P30-CA016058"],"award-info":[{"award-number":["2P30-CA016058"]}],"id":[{"id":"10.13039\/100012482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI139198"],"award-info":[{"award-number":["R01 AI139198"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmc.2024.117907","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:35:28Z","timestamp":1725636928000},"page":"117907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["N-substituted-4-(pyridin-4-ylalkyl)piperazine-1-carboxamides and related compounds as Leishmania CYP51 and CYP5122A1 inhibitors"],"prefix":"10.1016","volume":"113","author":[{"given":"Chris","family":"La Rosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Junaid Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiru","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allie","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitriy","family":"Uchenik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somrita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samrat","family":"Moitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zhuo Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-7241","authenticated-orcid":false,"given":"Karl A.","family":"Werbovetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117907_b0005","first-page":"467","article-title":"Sterol 14\u03b1-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms","volume":"1770","author":"Lepesheva","year":"2007","journal-title":"BBA"},{"key":"10.1016\/j.bmc.2024.117907_b0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fmicb.2019.00691","article-title":"The fungal CYP51s: their functions, structures, related drug resistance, and inhibitors","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmc.2024.117907_b0015","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117907_b0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2019.07.011","article-title":"Isavuconazole and voriconazole inhibition of sterol 14\u03b1-demethylases (CYP51) from Aspergillus fumigatus and Homo sapiens","volume":"54","author":"Warrilow","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmc.2024.117907_b0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1083\/jcb.200705076","article-title":"Ergosterol promotes pheromone signaling and plasma membrane fusion in mating yeast","volume":"180","author":"Jin","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bmc.2024.117907_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104240","article-title":"History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action","volume":"104","author":"Shafiei","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0035","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1073\/pnas.1324245111","article-title":"Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer","volume":"111","author":"Monk","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117907_b0040","doi-asserted-by":"crossref","first-page":"e0167485","DOI":"10.1371\/journal.pone.0167485","article-title":"Structural and functional elucidation of yeast lanosterol 14\u03b1-demethylase in complex with agrochemical antifungals","volume":"11","author":"Tyndall","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117907_b0045","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.42.7.1771","article-title":"Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies","volume":"42","author":"Urbina","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117907_b0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.44.1.150-155.2000","article-title":"Activities of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts","volume":"44","author":"Molina","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117907_b0055","doi-asserted-by":"crossref","unstructured":"Molina, I.; G\u00f3mez i Prat, J.; Salvador, F.; Trevi\u00f1o, B.; Sulleiro, E.; Serre, N.; Pou, D.; Roure, S.; Cabezos, J.; Valerio, L.; Blanco-Grau, A.; S\u00e1nchez-Montalv\u00e1, A.; Vidal, X.; Pahissa, A., Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N. Engl. J. Med. 2014, 370, 1899-1908.","DOI":"10.1056\/NEJMoa1313122"},{"key":"10.1016\/j.bmc.2024.117907_b0060","doi-asserted-by":"crossref","first-page":"e0186117","DOI":"10.1371\/journal.pone.0186117","article-title":"Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis","volume":"12","author":"Galv\u00e3o","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117907_b0065","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4269\/ajtmh.22-0733","article-title":"Treatment of cutaneous leishmaniasis with allopurinol plus itraconazole in Iran","volume":"108","author":"Mashayekhi Goyonlo","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2024.117907_b0070","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/0140-6736(90)93358-V","article-title":"Ketoconazole in visceral leishmaniasis","volume":"336","author":"Sundar","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117907_b0075","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(05)64828-3","article-title":"Treatment of kala-azar with oral fluconazole","volume":"348","author":"Sundar","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117907_b0080","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1021\/jm900030h","article-title":"Structurally simple inhibitors of lanosterol 14\u03b1-demethylase are efficacious in a rodent model of acute Chagas disease","volume":"52","author":"Suryadevara","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0085","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/AAC.06244-11","article-title":"Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib","volume":"56","author":"Buckner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117907_b0090","doi-asserted-by":"crossref","first-page":"e1736","DOI":"10.1371\/journal.pntd.0001736","article-title":"Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51","volume":"6","author":"Gunatilleke","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0095","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiv228","article-title":"VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral leishmaniasis","volume":"212","author":"Lepesheva","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0100","doi-asserted-by":"crossref","first-page":"10910","DOI":"10.1021\/acs.jmedchem.8b01671","article-title":"Sterol 14\u03b1-demethylase structure-based optimization of drug candidates for human infections with the protozoan trypanosomatidae","volume":"61","author":"Friggeri","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0105","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/acsinfecdis.0c00855","article-title":"Synthesis and antileishmanial evaluation of arylimidamide-azole hybrids containing a phenoxyalkyl linker","volume":"7","author":"Abdelhameed","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0110","doi-asserted-by":"crossref","first-page":"e25273","DOI":"10.1371\/journal.pone.0025273","article-title":"CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani","volume":"6","author":"Verma","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117907_b0115","article-title":"CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles","author":"Jin","year":"2023","journal-title":"Res Sq"},{"key":"10.1016\/j.bmc.2024.117907_b0120","first-page":"1377","article-title":"Investigation of the rate-determining microsomal reaction of cholesterol biosynthesis from lanosterol in Morris hepatomas and liver","volume":"37","author":"Williams","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2024.117907_b0125","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1073\/pnas.1802930115","article-title":"C-4 sterol demethylation enzymes distinguish bacterial and eukaryotic sterol synthesis","volume":"115","author":"Lee","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117907_b0130","unstructured":"Werbovetz, K.; Sharma, P.; La Rosa, C.; Wang, Z.; Jin, Y.; Feng, M. Compounds for treating infections with parasitic protozoa. WO2024059333A1, 2024."},{"key":"10.1016\/j.bmc.2024.117907_b0135","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1039\/b506404j","article-title":"New prodrugs derived from 6-aminodopamine and 4-aminophenol as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT)","volume":"3","author":"Knaggs","year":"2005","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0140","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117907_b0145","doi-asserted-by":"crossref","first-page":"e1671","DOI":"10.1371\/journal.pntd.0001671","article-title":"An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages","volume":"6","author":"Siqueira-Neto","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0150","doi-asserted-by":"crossref","unstructured":"Joice, A.; Yang, S.; Farahat, A.; Meeds, H.; Feng, M.; Li, J.; Boykin, D.; Wang, M.; Werbovetz, K., Antileishmanial efficacy and pharmacokinetics of DB766-azole combinations. Antimicrob Agents Chemother 2018, 62, e01129-17.","DOI":"10.1128\/AAC.01129-17"},{"key":"10.1016\/j.bmc.2024.117907_b0155","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1074\/jbc.M112.438754","article-title":"Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response","volume":"288","author":"Mast","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0160","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.118.082032","article-title":"Comparison of antifungal azole interactions with adult cytochrome P450 3A4 versus neonatal cytochrome P450 3A7","volume":"46","author":"Godamudunage","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117907_b0165","first-page":"27","article-title":"Sterol profiling of Leishmania parasites using a new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway","volume":"20","author":"Feng","year":"2022","journal-title":"Int J Parasitol: Drugs Drug Resist"},{"key":"10.1016\/j.bmc.2024.117907_b0170","doi-asserted-by":"crossref","first-page":"26838","DOI":"10.1074\/jbc.M111.237099","article-title":"Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14\u03b1-demethylase (CYP51) from Leishmania infantum","volume":"286","author":"Hargrove","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/mmi.14139","article-title":"Sterol methyltransferase is required for optimal mitochondrial function and virulence in Leishmania major","volume":"111","author":"Mukherjee","year":"2019","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.bmc.2024.117907_b0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0166-6851(88)90166-1","article-title":"Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes","volume":"31","author":"Beach","year":"1988","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.bmc.2024.117907_b0185","doi-asserted-by":"crossref","first-page":"e0003588","DOI":"10.1371\/journal.pntd.0003588","article-title":"Targeting ergosterol biosynthesis in Leishmania donovani: Essentiality of sterol 14alpha-demethylase","volume":"9","author":"McCall","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0190","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1371\/journal.pntd.0000372","article-title":"Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit","volume":"3","author":"Chen","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0195","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/jm401067s","article-title":"Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents","volume":"56","author":"Choi","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0200","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.1021\/jm500448u","article-title":"4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency","volume":"57","author":"Calvet","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0205","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/s41598-018-22043-z","article-title":"3-Pyridyl inhibitors with novel activity against Trypanosoma cruzi reveal in vitro profiles can aid prediction of putative cytochrome P450 inhibition","volume":"8","author":"Sykes","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.117907_b0210","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1021\/jm400012e","article-title":"Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth","volume":"56","author":"Andriani","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0215","doi-asserted-by":"crossref","first-page":"e0004014","DOI":"10.1371\/journal.pntd.0004014","article-title":"Development of a fluorescence-based Trypanosoma cruzi CYP51 inhibition assay for effective compound triaging in drug discovery programmes for Chagas disease","volume":"9","author":"Riley","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2024.117907_b0220","doi-asserted-by":"crossref","first-page":"e1004427","DOI":"10.1371\/journal.ppat.1004427","article-title":"Sterol biosynthesis is required for heat resistance but not extracellular survival in Leishmania","volume":"10","author":"Xu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmc.2024.117907_b0225","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/jo971176v","article-title":"NMR chemical shifts of common laboratory solvents as trace impurities","volume":"62","author":"Gottlieb","year":"1997","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0230","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/tx00025a013","article-title":"Evidence that a hemoglobin adduct of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a 4-(3-pyridyl)-4-oxobutyl carboxylic acid ester","volume":"5","author":"Carmella","year":"1992","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2024.117907_b0235","unstructured":"Xia, A.; Ma, A.; Ge, M.; Xu, D. N-heterocyclic carbene ligand, preparation method and application thereof. CN117903058A, 2024."},{"key":"10.1016\/j.bmc.2024.117907_b0240","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bmc.2017.11.036","article-title":"Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy","volume":"26","author":"Yeon","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0245","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1021\/acscatal.9b02316","article-title":"Microballs containing Ni(0)Pd(0) nanoparticles for highly selective micellar catalysis in water","volume":"9","author":"Bihani","year":"2019","journal-title":"ACS Catal"},{"key":"10.1016\/j.bmc.2024.117907_b0250","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmc.2015.02.020","article-title":"SAR refinement of antileishmanial N2, N4-disubstituted quinazoline-2,4-diamines","volume":"23","author":"Zhu","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117907_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126725","article-title":"Synthesis and antileishmanial evaluation of thiazole orange analogs","volume":"30","author":"Abdelhameed","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117907_b0260","first-page":"1084","article-title":"Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression","volume":"10","author":"Kapler","year":"1990","journal-title":"Mol Cell Biol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:30:56Z","timestamp":1728491456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624003213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"alternative-id":["S0968089624003213"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117907","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-substituted-4-(pyridin-4-ylalkyl)piperazine-1-carboxamides and related compounds as Leishmania CYP51 and CYP5122A1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117907"}}